SV1996000030A - Proteinas recombinantes para obesidad (ob), ref. 13209-sv - Google Patents
Proteinas recombinantes para obesidad (ob), ref. 13209-svInfo
- Publication number
- SV1996000030A SV1996000030A SV1996000030A SV1996000030A SV1996000030A SV 1996000030 A SV1996000030 A SV 1996000030A SV 1996000030 A SV1996000030 A SV 1996000030A SV 1996000030 A SV1996000030 A SV 1996000030A SV 1996000030 A SV1996000030 A SV 1996000030A
- Authority
- SV
- El Salvador
- Prior art keywords
- obesity
- ref
- recombinant proteins
- proteins
- modulate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Abstract
PROTEINAS QUE MODULAN EL PESO CORPORAL DE ANIMALES Y HUMANOS PARA EL TRATAMIENTO, PREVENCION Y CONTROL DE LA OBESIDAD Y ENFERMEDADES O CONDICIONES ASOCIADAS Y LA EXPRESION RECOMBINANTE DE ESTAS PROTEINAS BIOLOGICAMENTE ACTIVAS EN FORMAS PURIFICADAS Y HOMOGENEAS.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43577795A | 1995-05-05 | 1995-05-05 | |
US48462995A | 1995-06-07 | 1995-06-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
SV1996000030A true SV1996000030A (es) | 1999-01-14 |
Family
ID=27030682
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SV1996000030A SV1996000030A (es) | 1995-05-05 | 1996-05-03 | Proteinas recombinantes para obesidad (ob), ref. 13209-sv |
Country Status (35)
Country | Link |
---|---|
US (1) | US6025325A (es) |
EP (1) | EP0741187A2 (es) |
JP (1) | JP3244627B2 (es) |
KR (1) | KR100219970B1 (es) |
CN (1) | CN1157290A (es) |
AR (1) | AR003087A1 (es) |
AU (1) | AU688210B2 (es) |
BG (1) | BG62975B1 (es) |
BR (1) | BR9602166A (es) |
CA (1) | CA2175298A1 (es) |
CZ (1) | CZ129796A3 (es) |
DE (1) | DE741187T1 (es) |
ES (1) | ES2093593T1 (es) |
GR (1) | GR960300075T1 (es) |
HR (1) | HRP960213A2 (es) |
HU (1) | HU220093B (es) |
IL (1) | IL118059A0 (es) |
IS (1) | IS4343A (es) |
MA (1) | MA23856A1 (es) |
MY (1) | MY132189A (es) |
NO (1) | NO961796L (es) |
NZ (1) | NZ286466A (es) |
OA (1) | OA10362A (es) |
PE (1) | PE50897A1 (es) |
PL (1) | PL186568B1 (es) |
RO (1) | RO117177B1 (es) |
RU (1) | RU96109211A (es) |
SG (1) | SG49337A1 (es) |
SK (1) | SK56996A3 (es) |
SV (1) | SV1996000030A (es) |
TN (1) | TNSN96066A1 (es) |
TR (1) | TR199600357A2 (es) |
TW (1) | TW464655B (es) |
UY (1) | UY24219A1 (es) |
YU (1) | YU26596A (es) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3504263B2 (ja) | 1991-11-04 | 2004-03-08 | ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー | 組み換え型骨形態形成蛋白ヘテロダイマー、組成物および使用法 |
US6479055B1 (en) * | 1993-06-07 | 2002-11-12 | Trimeris, Inc. | Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission |
US6124448A (en) * | 1994-08-17 | 2000-09-26 | The Rockfeller University | Nucleic acid primers and probes for the mammalian OB gene |
US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
US6471956B1 (en) | 1994-08-17 | 2002-10-29 | The Rockefeller University | Ob polypeptides, modified forms and compositions thereto |
US6048837A (en) * | 1994-08-17 | 2000-04-11 | The Rockefeller University | OB polypeptides as modulators of body weight |
US6350730B1 (en) | 1994-08-17 | 2002-02-26 | The Rockefeller University | OB polypeptides and modified forms as modulators of body weight |
US6429290B1 (en) | 1994-08-17 | 2002-08-06 | The Rockefeller University | OB polypeptides, modified forms and derivatives |
US6001968A (en) | 1994-08-17 | 1999-12-14 | The Rockefeller University | OB polypeptides, modified forms and compositions |
US6936439B2 (en) * | 1995-11-22 | 2005-08-30 | Amgen Inc. | OB fusion protein compositions and methods |
US20030040467A1 (en) * | 1998-06-15 | 2003-02-27 | Mary Ann Pelleymounter | Ig/ob fusions and uses thereof. |
US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
AU769250B2 (en) * | 1995-12-27 | 2004-01-22 | Genentech Inc. | OB protein derivatives having prolonged half-life |
ATE267255T1 (de) * | 1995-12-27 | 2004-06-15 | Genentech Inc | Ob proteinderivate mit verlängerter halbwertzeit |
US6541604B1 (en) * | 1996-01-08 | 2003-04-01 | Genentech, Inc. | Leptin receptor having a WSX motif |
US20050019325A1 (en) | 1996-01-08 | 2005-01-27 | Carter Paul J. | WSX receptor agonist antibodies |
US7074397B1 (en) * | 1996-01-08 | 2006-07-11 | Genentech, Inc. | Method for enhancing proliferation or differentiation of a cell using ob protein |
US5831017A (en) * | 1996-01-25 | 1998-11-03 | Eli Lilly And Company | Obesity protein analog compounds and formulations thereof |
US7067472B1 (en) * | 1996-06-04 | 2006-06-27 | The Scripps Research Institute | Diagnostic and therapeutic methods related to regulating energy mobilization with OB protein and OB antibodies |
US20060205660A1 (en) * | 1996-06-20 | 2006-09-14 | Sauvage Frederic D | OB protein-immunoglobulin chimeras |
US6001816A (en) * | 1996-06-20 | 1999-12-14 | Merck & Co., Inc. | Gene therapy for leptin deficiency |
US20030036629A1 (en) * | 1997-12-12 | 2003-02-20 | Barry Foster | Novel tgf-beta protein purification methods |
US6656906B1 (en) | 1998-05-20 | 2003-12-02 | Trimeris, Inc. | Hybrid polypeptides with enhanced pharmacokinetic properties |
US6420339B1 (en) * | 1998-10-14 | 2002-07-16 | Amgen Inc. | Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility |
US7169889B1 (en) * | 1999-06-19 | 2007-01-30 | Biocon Limited | Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin |
CZ299516B6 (cs) * | 1999-07-02 | 2008-08-20 | F. Hoffmann-La Roche Ag | Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem |
JO2291B1 (en) | 1999-07-02 | 2005-09-12 | اف . هوفمان لاروش ايه جي | Erythropoietin derivatives |
US7446183B2 (en) | 2000-06-16 | 2008-11-04 | Asterion Limited | Fusion protein comprising growth hormone and growth hormone receptor |
US20030054015A1 (en) * | 2000-12-25 | 2003-03-20 | Shinichiro Haze | Sympathetic-activating perfume composition |
US6867183B2 (en) * | 2001-02-15 | 2005-03-15 | Nobex Corporation | Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith |
US7060675B2 (en) * | 2001-02-15 | 2006-06-13 | Nobex Corporation | Methods of treating diabetes mellitus |
EP1234583A1 (en) | 2001-02-23 | 2002-08-28 | F. Hoffmann-La Roche Ag | PEG-conjugates of HGF-NK4 |
US6828305B2 (en) * | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US7713932B2 (en) | 2001-06-04 | 2010-05-11 | Biocon Limited | Calcitonin drug-oligomer conjugates, and uses thereof |
US6835802B2 (en) | 2001-06-04 | 2004-12-28 | Nobex Corporation | Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties |
US6828297B2 (en) * | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US6713452B2 (en) | 2001-06-04 | 2004-03-30 | Nobex Corporation | Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US7030082B2 (en) * | 2001-09-07 | 2006-04-18 | Nobex Corporation | Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith |
US7196059B2 (en) * | 2001-09-07 | 2007-03-27 | Biocon Limited | Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith |
US7312192B2 (en) * | 2001-09-07 | 2007-12-25 | Biocon Limited | Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
US7166571B2 (en) * | 2001-09-07 | 2007-01-23 | Biocon Limited | Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
US6913903B2 (en) * | 2001-09-07 | 2005-07-05 | Nobex Corporation | Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
US6770625B2 (en) | 2001-09-07 | 2004-08-03 | Nobex Corporation | Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith |
PL214862B1 (pl) | 2001-10-22 | 2013-09-30 | Amgen | Sposób in vitro do okreslania predyspozycji pacjenta ludzkiego z lipoatrofia do reagowania na leczenie bialkiem leptyny, kompozycje farmaceutyczne do zastosowania do leczenia lipoatrofii i kompozycje farmaceutyczne zawierajace bialko leptyny |
AU2003225277A1 (en) * | 2002-05-02 | 2003-11-17 | Robert Harris | Lipid removal from the body |
CN1878565B (zh) | 2003-09-12 | 2011-01-12 | 惠氏公司 | 用于递送成骨蛋白的注射型磷酸钙固体小棒剂和糊剂 |
CA2910494C (en) | 2004-07-19 | 2018-10-23 | Biocon Limited | Insulin-oligomer conjugates, formulations and uses thereof |
US8227408B2 (en) * | 2005-09-07 | 2012-07-24 | Neurotez, Inc. | Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology |
MX2010003979A (es) * | 2007-10-16 | 2010-06-02 | Biocon Ltd | Composicion farmaceutica oralmente administrable y proceso para su preparacion. |
CA2725143A1 (en) * | 2008-05-21 | 2009-11-26 | Neurotez, Inc. | Methods for treating progressive cognitive disorders related to neurofibrillary tangles |
EP2352510A4 (en) * | 2008-11-04 | 2012-08-29 | Neurotez Inc | LEPTIN COMPOSITIONS AND METHODS OF TREATING PROGRESSIVE COGNITIVE DISORDERS DUE TO THE ASSEMBLY OF NEUROFIBRILLARY BUNNELS AND AMYLOID BETA |
JP2012523434A (ja) | 2009-04-10 | 2012-10-04 | アミリン・ファーマシューティカルズ,インコーポレイテッド | エストロゲン欠乏哺乳類のためのアミリンアゴニスト化合物 |
ES2641869T3 (es) | 2010-09-28 | 2017-11-14 | Aegerion Pharmaceuticals, Inc. | Polipéptidos de fusión de leptina-ABD con duración de acción aumentada |
BR112013018628A2 (pt) | 2011-01-26 | 2017-07-18 | Novo Nordisk As | derivados da leptina |
WO2021113434A1 (en) * | 2019-12-03 | 2021-06-10 | Rodan & Fields, Llc | Peptides and compositions for inhibiting hair growth |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4199337A (en) * | 1978-10-06 | 1980-04-22 | International Telephone And Telegraph Corporation | Method of fabricating high strength optical preforms |
US4666836A (en) * | 1981-01-02 | 1987-05-19 | The Research Foundation Of State University Of New York | Novel cloning vehicles for polypeptide expression in microbial hosts |
DE3380726D1 (en) * | 1982-06-24 | 1989-11-23 | Japan Chem Res | Long-acting composition |
US4643969A (en) * | 1983-07-25 | 1987-02-17 | The Research Foundation Of State University Of New York | Novel cloning vehicles for polypeptide expression in microbial hosts |
US4757013A (en) * | 1983-07-25 | 1988-07-12 | The Research Foundation Of State University Of New York | Cloning vehicles for polypeptide expression in microbial hosts |
EP0154316B1 (en) * | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
US5595732A (en) * | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
US5643575A (en) * | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US6309853B1 (en) * | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
AU3329895A (en) * | 1994-08-17 | 1996-03-07 | Rockefeller University, The | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
US5861485A (en) * | 1994-08-23 | 1999-01-19 | Millennium Pharmaceuticals, Inc. | Polypeptides involved in body weight disorders, including obesity |
US5932462A (en) * | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
US5827734A (en) * | 1995-01-20 | 1998-10-27 | University Of Washington | Materials and methods for determining ob protein in a biological sample |
US5569743A (en) * | 1995-01-31 | 1996-10-29 | Eli Lilly And Company | Anti-obesity proteins |
US5567678A (en) * | 1995-01-31 | 1996-10-22 | Eli Lilly And Company | Anti-obesity proteins |
US5574133A (en) * | 1995-01-31 | 1996-11-12 | Eli Lilly And Company | Anti-obesity proteins |
US5563244A (en) * | 1995-01-31 | 1996-10-08 | Eli Lilly And Company | Anti-obesity proteins |
US5559208A (en) * | 1995-01-31 | 1996-09-24 | Eli Lilly And Company | Anti-obesity proteins |
US5580954A (en) * | 1995-01-31 | 1996-12-03 | Eli Lilly And Company | Anti-obesity proteins |
US5569744A (en) * | 1995-01-31 | 1996-10-29 | Eli Lilly And Company | Anti-obesity proteins |
US5594104A (en) * | 1995-01-31 | 1997-01-14 | Eli Lilly And Company | Anti-obesity proteins |
US5567803A (en) * | 1995-01-31 | 1996-10-22 | Eli Lilly And Company | Anti-obesity proteins |
US5563243A (en) * | 1995-01-31 | 1996-10-08 | Eli Lilly And Company | Anti-obesity proteins |
US5563245A (en) * | 1995-01-31 | 1996-10-08 | Eli Lilly And Company | Anti-obesity proteins |
WO1996023515A1 (en) * | 1995-01-31 | 1996-08-08 | Eli Lilly And Company | Anti-obesity proteins |
US5554727A (en) * | 1995-01-31 | 1996-09-10 | Eli Lilly And Company | Anti-obesity proteins |
WO1996031526A1 (en) * | 1995-04-06 | 1996-10-10 | Amylin Pharmaceuticals, Inc. | Anti-obesity agents |
WO1996040912A1 (en) * | 1995-06-07 | 1996-12-19 | Amgen Inc. | Ob protein compositions and method |
AU1406497A (en) * | 1995-12-06 | 1997-06-27 | Schering Corporation | Mutational variants of mammalian ob gene proteins |
ATE267255T1 (de) * | 1995-12-27 | 2004-06-15 | Genentech Inc | Ob proteinderivate mit verlängerter halbwertzeit |
-
1996
- 1996-04-24 EP EP96106408A patent/EP0741187A2/en not_active Ceased
- 1996-04-24 DE DE0741187T patent/DE741187T1/de active Pending
- 1996-04-24 ES ES96106408T patent/ES2093593T1/es active Pending
- 1996-04-29 CA CA002175298A patent/CA2175298A1/en not_active Abandoned
- 1996-04-29 IL IL11805996A patent/IL118059A0/xx unknown
- 1996-04-29 NZ NZ286466A patent/NZ286466A/en unknown
- 1996-04-29 HU HU9601120A patent/HU220093B/hu not_active IP Right Cessation
- 1996-04-30 RU RU96109211/04A patent/RU96109211A/ru not_active Application Discontinuation
- 1996-04-30 PL PL96314051A patent/PL186568B1/pl unknown
- 1996-04-30 AU AU51978/96A patent/AU688210B2/en not_active Withdrawn - After Issue
- 1996-05-02 PE PE1996000300A patent/PE50897A1/es not_active Application Discontinuation
- 1996-05-02 AR ARP960102430A patent/AR003087A1/es not_active Application Discontinuation
- 1996-05-02 HR HR08/484,629A patent/HRP960213A2/hr not_active Application Discontinuation
- 1996-05-02 MA MA24221A patent/MA23856A1/fr unknown
- 1996-05-02 SG SG1996009690A patent/SG49337A1/en unknown
- 1996-05-03 BG BG100558A patent/BG62975B1/bg unknown
- 1996-05-03 SV SV1996000030A patent/SV1996000030A/es not_active Application Discontinuation
- 1996-05-03 CZ CZ961297A patent/CZ129796A3/cs unknown
- 1996-05-03 MY MYPI96001683A patent/MY132189A/en unknown
- 1996-05-03 IS IS4343A patent/IS4343A/is unknown
- 1996-05-03 UY UY24219A patent/UY24219A1/es unknown
- 1996-05-03 SK SK569-96A patent/SK56996A3/sk unknown
- 1996-05-03 RO RO96-00920A patent/RO117177B1/ro unknown
- 1996-05-03 TR TR96/00357A patent/TR199600357A2/xx unknown
- 1996-05-03 OA OA60824D patent/OA10362A/fr unknown
- 1996-05-03 CN CN96104497A patent/CN1157290A/zh active Pending
- 1996-05-03 NO NO961796A patent/NO961796L/no not_active Application Discontinuation
- 1996-05-03 TN TNTNSN96066A patent/TNSN96066A1/fr unknown
- 1996-05-04 KR KR1019960014570A patent/KR100219970B1/ko not_active IP Right Cessation
- 1996-05-04 TW TW085105350A patent/TW464655B/zh not_active IP Right Cessation
- 1996-05-06 BR BR9602166A patent/BR9602166A/pt not_active Application Discontinuation
- 1996-05-06 YU YU26596A patent/YU26596A/sh unknown
- 1996-05-07 JP JP11273996A patent/JP3244627B2/ja not_active Expired - Fee Related
- 1996-05-15 US US08/648,263 patent/US6025325A/en not_active Expired - Fee Related
- 1996-12-31 GR GR960300075T patent/GR960300075T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SV1996000030A (es) | Proteinas recombinantes para obesidad (ob), ref. 13209-sv | |
DE69719798D1 (de) | Periphäre verabreichung von glp-1 analogen und derivate zur reguleirung der fettleibigkeit | |
DE69839014D1 (de) | Apolipoprotein a-i agonisten und deren verwendung zur behandlung dyslipidämischer erkrankungen | |
MX9202030A (es) | Expresion recombinante de subunidades de analogo de exotoxina de colera. | |
DK0960127T3 (da) | Isoleret dimert fibroblastaktiverende protein-alfa og anvendelser deraf | |
NO952744L (no) | Cytokinbegrensende midler | |
BR9406720A (pt) | Utilização de um adenovírus recombinante de origem animal adenovírus recombinante de origem animal e composição farmacêutica compreendendo um ou vários adenovírus | |
HK1014191A1 (en) | Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof | |
HUP0103114A2 (hu) | Apolipoprotein A-1 agonisták és alkalmazásuk diszlipidémiás rendellenességek kezelésében | |
FI954978A (fi) | Modifioidut proteiini- ja peptidilääkeaineet | |
DE60034865D1 (de) | Alloferone - immunomodulierende Peptide | |
ES2056180T3 (es) | Nuevos derivados de 2'-halometiliden, 2'-eteniliden y 2'-etinil citidina. | |
ES2180948T3 (es) | Peptido que proviene de una forma soluble de la acetilcolinesterasa, activo como modulador del canal. | |
ES2087337T3 (es) | Composiciones de implantes que contienen una proteina, peptido o polipeptido biologicamente activos. | |
ES2110057T3 (es) | Composicion medicinal que contiene tcf-ii. | |
TR199802504T2 (xx) | N�rotoksik yaralanmalar�n tedavisi i�in bukminsterflirin kullan�lmas�. | |
FR2786100B1 (fr) | Nouvelle application therapeutique de la nicergoline | |
KR100488038B1 (ko) | 기관 보호 활성을 지닌 신규한 신체 보호 화합물 펩티드염, 이의 제조 방법 및 치료에서의 이의 용도 | |
ECSP961740A (es) | Proteinas obesas (ob) recombinantes ram 4105/175 | |
DE69630948T2 (de) | Peptide und medikamente für knochenkrankheiten welche diese peptide als aktive bestandteile beinhalten | |
HUP9901183A2 (hu) | Készítmények és eljárások az orális mukozitisz megakadályozására és kezelésére | |
MX9301694A (es) | Peptidos antivirales | |
KR920014480A (ko) | 기흉 치료용 제약 조성물을 제조하기 위한 인간 인터류킨 2의 활성을 갖는 폴리펩티드의 용도 | |
Critical Care Society of South Africa Working Group | Severe sepsis and the role of novel therapeutic agents. Position statement of the Critical Care Society of South Africa on severe sepsis and the role of novel therapeutic agents such as drotrecogin alfa (activated) | |
MX9604539A (es) | Aminoacidos modificados para la distribucion de farmaco. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Lapse |